Sana Biotechnology, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Sana is a preclinical-stage cell and gene engineering company with no approved products and no product revenue. Although the request identifies Q4 2022, this filing reports full-year results; it does not provide a clear standalone Q4 financial summary in the supplied text.
Key financial metrics and liquidity
| Metric | FY2022 / Dec. 31, 2022 | Prior comparable period |
|---|---|---|
| Revenue | No product revenue | No product revenue reported |
| Research and development expense | $285.9 million | $248.6 million in 2021 |
| General and administrative expense | $71.6 million | $50.4 million in 2021 |
| Total operating expenses | $272.6 million, including an $84.9 million net gain from revaluing success-payment and contingent-consideration liabilities | $356.9 million, including $57.9 million of such expense in 2021 |
| Net loss | $269.5 million; $1.43 per share | $355.9 million; $2.14 per share in 2021 |
| Net cash used in operating activities | $290.1 million | $251.1 million in 2021 |
| Cash, cash equivalents, and marketable securities | $434.0 million | $746.9 million at Dec. 31, 2021 |
| Debt | No debt outstanding | Not stated here for comparison |
Gross margin and conventional operating margins are not meaningful because Sana has no product sales. Current assets were $444.4 million and current liabilities were $111.5 million. Management said year-end cash, cash equivalents, and marketable securities were expected to fund operations and capital expenditures for at least 12 months, based on current plans and assumptions. Restricted cash totaled $10.5 million and was reported separately.
Material changes versus 2021
- Net loss narrowed by $86.5 million, chiefly because liability revaluations produced an $84.9 million gain in 2022 versus a $57.9 million expense in 2021. These are non-cash, valuation-sensitive items; they do not represent operating cash generation.
- Research and development expense rose $37.3 million, reflecting higher personnel, laboratory, facility, and third-party manufacturing costs. The increase was partly offset by lower technology-licensing expense: 2021 included a $50.0 million Beam upfront payment, while 2022 included $6.0 million related to CD22 and BCMA programs.
- Operating cash use increased by $39.0 million to $290.1 million. Cash and marketable securities declined from $746.9 million to $434.0 million.
- In November 2022, Sana prioritized programs nearer clinical development and reduced its workforce by approximately 15%. It recorded $6.8 million of severance and related costs and $1.9 million of non-cash stock compensation related to affected employees.
Outlook, developments, and risks
- Clinical and pipeline milestones: FDA clearance for the SC291 CD19 allogeneic CAR T IND occurred in January 2023, after year-end. Sana expected initial clinical data in 2023. It targeted an IND for SC262 in 2023, and potential IND submissions for SC255, SC451, and SC379 as early as 2024. These are forward-looking plans, not achieved milestones.
- Other clinical research: Sana planned to support an investigator-sponsored trial of hypoimmune primary islet cells in type 1 diabetes patients in 2023, with data potentially available as early as the second half of 2023. Sana cautions that it does not control the trial’s conduct or timing.
- Manufacturing and leases: Sana shifted its planned GMP manufacturing facility from Fremont, California, to Bothell, Washington. It intended to sublease or terminate the Fremont lease, with no assurance of acceptable terms. The Bothell facility was expected to take several years to operationalize. Undiscounted operating-lease commitments totaled $217.4 million; the balance sheet reported $108.3 million of operating-lease liabilities.
- Funding and obligations: Sana expects continued losses and anticipates needing additional financing in the future. It had an ATM program allowing up to $150 million of stock sales, but had raised only about $0.6 million net by year-end. Potential Cobalt contingent consideration is up to $500 million, and Cobalt and Harvard success payments could also be substantial; none had been triggered as of December 31, 2022. Their fair-value remeasurements can materially affect reported earnings.
- Principal risks: The platforms are novel and unproven in humans; clinical, regulatory, safety, and manufacturing outcomes are uncertain. Other material risks include reliance on CDMOs and specialized suppliers, donor-cell availability, intellectual-property licenses and disputes, competition, cash needs, talent retention, and inflation or geopolitical disruption.
Most important facts for investors to verify
- Whether SC291 and the planned islet-cell trial produced interpretable human data, and whether results support the hypoimmune platform’s intended persistence and safety claims.
- Current cash, cash burn, financing activity, and the assumptions behind management’s stated runway; operating cash use exceeded the reported net loss in 2022.
- Progress, costs, and timing for the Bothell manufacturing facility, and whether the Fremont lease was subleased or terminated.
- Changes in the probability, timing, and fair value of Cobalt contingent consideration and Cobalt and Harvard success-payment obligations.
- Whether planned IND submissions and clinical milestones were achieved, delayed, or reprioritized, and how any restructuring affects execution.